COMPARISON
Angiotensin II vs Octreotide
6 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Angiotensin II is authorised or registered in 3 and Octreotide in 10 of the 10 registers read. Angiotensin II: highest phase Phase 4 (after approval). Octreotide: highest phase Phase 4 (after approval). 1 registered trial includes both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Angiotensin II | Octreotide | |
|---|---|---|
| Registered trials differs | 364 clinicaltrials.gov · 2026-10-03 | 344 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: ANGIOTENSIN II openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Octreotide Acetate openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2019-08-23 ema · 2026-10-03 | 2025-06-30 ema · 2026-10-03 |
| EU withdrawn on differs | Not checked no record of "withdrawnOn" for angiotensin-ii | 2022-12-02 ema · 2026-10-03 |
| ATC code differs | C09 ema · 2026-10-03 | H01CB02 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Angiotensin II | placebo | Octreotide | placebo |
|---|---|---|---|---|
| Anaemia | 6.7% | 5.7% | 24.3% | 9.1% |
| Hypertension | 5.5% | 5.7% | 26.5% | 19.4% |
| Multi-organ failure | 15.3% | 14.6% | - | - |
| Septic shock | 11.0% | 6.3% | - | - |
| Atrial fibrillation | 10.4% | 10.1% | - | - |
| Thrombocytopenia | 9.2% | 6.3% | - | - |
| Hypokalaemia | 8.0% | 6.3% | - | - |
| Hypotension | 8.0% | 4.4% | - | - |
| Delirium | 5.5% | 0.6% | - | - |
| Pleural effusion | 4.9% | 5.1% | - | - |
| Diarrhoea | - | - | 46.2% | 31.7% |
| Oedema peripheral | - | - | 34.9% | 19.6% |
| Asthenia | - | - | 33.3% | 20.9% |
| Nausea | - | - | 30.8% | 21.2% |
| Fatigue | - | - | 29.8% | 27.7% |
| Rash | - | - | 28.8% | 14.1% |
| Decreased appetite | - | - | 28.5% | 15.2% |
| Dyspnoea | - | - | 25.9% | 9.1% |
Trial register Angiotensin II: 1 placebo-controlled trials; Octreotide: 5. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Angiotensin II side effects · Octreotide side effects
LEGAL STATUS
Approval in each country read
| Country | Angiotensin II | Octreotide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Not on the register | Authorised | Regulator Health Canada |
| Australia | Status unknown | Registered | TGA |
| Switzerland | Not on the register | Authorised | Regulator Swissmedic |
| Brazil | Not on the register | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Not on the register | Registered | Regulator HSA |
| Turkey | Not on the register | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
1 registered trial includes both
| NCT04048707 | Angiotensin 2 for Hepatorenal Syndrome WITHDRAWN · updated 2024-03-06 |
|---|
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.